SAB Biotherapeutics 과거 순이익 실적

과거 기준 점검 0/6

SAB Biotherapeutics 의 수입은 연평균 -19.7%의 비율로 감소해 온 반면, Biotechs 산업은 연평균 33.8%의 비율로 증가했습니다. 매출은 연평균 72.9%의 비율로 감소해 왔습니다.

핵심 정보

-19.73%

순이익 성장률

-16.86%

주당순이익(EPS) 성장률

Biotechs 산업 성장률	17.04%
매출 성장률	-72.94%
자기자본이익률	-0.18%
순이익률	n/a
최근 순이익 업데이트	31 Mar 2026

최근 과거 실적 업데이트

Recent updates

분석 기사 • Nov 22

We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

분석 기사 • Sep 22

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

분석 기사 • Apr 17

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders are no doubt pleased to see that the share price has bounced 42...

분석 기사 • Jan 20

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders will have a reason to smile today, with the analysts making...

분석 기사 • Nov 19

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues

Shareholders in SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) may be thrilled to learn that the analysts have just...

분석 기사 • Nov 18

Earnings Beat: SAB Biotherapeutics, Inc. (NASDAQ:SABS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) missed earnings with its latest third-quarter results, disappointing...

Seeking Alpha • Sep 28

SAB Bio rises as H1N1 influenza and COVID-19 treatments show efficacy in trial

SAB Biotherapeutics (NASDAQ:SABS) is trading 5.6% higher after the company said its fully-human polyclonal antibody platform maintains efficacy against multiple variants of several highly mutating viruses. A Phase 2a challenge trial showed SAB-176 reduced the viral load in subjects exposed to H1N1 influenza virus and improved symptoms by day four and shortened the timeframe for viral shedding. Another study showed that SAB-185 COVID-19 polyclonal antibody therapeutic candidate was effective in animal models against the majority of known SARS-CoV2 variants.

분석 기사 • Aug 12

What Does The Future Hold For SAB Biotherapeutics, Inc. (NASDAQ:SABS)? These Analysts Have Been Cutting Their Estimates

The latest analyst coverage could presage a bad day for SAB Biotherapeutics, Inc. ( NASDAQ:SABS ), with the analysts...

Seeking Alpha • Aug 10

SAB Biotherapeutics GAAP EPS of -$0.11 beats by $0.03

SAB Biotherapeutics press release (NASDAQ:SABS): Q2 GAAP EPS of -$0.11 beats by $0.03. Cash and cash equivalents were $16.6 million as of June 30, 2022, compared to $22.4 million on March 31, 2022, which was driven primarily by $0.7 million in further capital expansion and SAB’s second quarter cash operating loss of $5.1 million. Financial Guidance: Based on its current operating plans, SAB expects that its existing business plan, cash and cash equivalents, and anticipated cash flows as of June 30, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for the twelve months following the date our quarterly report on Form 10-Q was made available for issuance.

분석 기사 • Apr 06

Downgrade: Here's How Analysts See SAB Biotherapeutics, Inc. (NASDAQ:SABS) Performing In The Near Term

Market forces rained on the parade of SAB Biotherapeutics, Inc. ( NASDAQ:SABS ) shareholders today, when the analysts...

매출 및 비용 세부 내역

SAB Biotherapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.

순이익 및 매출 추이

NasdaqCM:SABS 매출, 비용 및 순이익 (USD Millions)
날짜	매출	순이익	일반관리비	연구개발비
31 Mar 26	0	-9	19	6
31 Dec 25	0	4	16	0
30 Sep 25	0	-4	12	1
30 Jun 25	0	-20	12	14
31 Mar 25	0	-34	13	0
31 Dec 24	1	-34	15	0
30 Sep 24	2	-46	26	22
30 Jun 24	3	-40	25	0
31 Mar 24	3	-40	25	0
31 Dec 23	2	-42	24	0
30 Sep 23	4	-27	12	0
30 Jun 23	6	-29	13	0
31 Mar 23	13	-27	15	0
31 Dec 22	24	-19	16	0
30 Sep 22	33	-22	21	0
30 Jun 22	44	-19	21	0
31 Mar 22	56	-18	19	0
31 Dec 21	61	-17	17	0
30 Sep 21	76	7	10	-11
30 Jun 21	78	17	10	0
31 Mar 21	66	21	9	0
31 Dec 20	55	20	7	0
31 Dec 19	3	-9	4	0

양질의 수익: SABS 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SABS는 현재 수익성이 없습니다.

잉여현금흐름 대비 순이익 분석

과거 순이익 성장 분석

수익추이: SABS은 수익성이 없으며 지난 5년 동안 손실이 연평균 19.7% 증가했습니다.

성장 가속화: 현재 수익성이 없어 지난 1년간 SABS의 수익 성장률을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SABS은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(43%)와 비교하기 어렵습니다.

자기자본이익률

높은 ROE: SABS는 현재 수익성이 없으므로 자본 수익률이 음수(-0.18%)입니다.

총자산이익률

투하자본수익률

우수한 과거 실적 기업을 찾아보세요

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/05/22 07:41
종가	2026/05/22 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

SAB Biotherapeutics, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Kumaraguru Raja	Brookline Capital Markets
Keay Nakae	Chardan Capital Markets, LLC
Samantha Lynn Semenkow	Citigroup Inc

SAB Biotherapeutics 과거 순이익 실적

과거 기준 점검 0/6

핵심 정보

최근 과거 실적 업데이트

SAB Biotherapeutics, Inc. to Report Q1, 2026 Results on May 12, 2026

First half 2025 earnings released: US$1.65 loss per share (vs US$1.34 loss in 1H 2024)

First quarter 2025 earnings released: US$0.56 loss per share (vs US$0.54 loss in 1Q 2024)

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2024 earnings released: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New major risk - Revenue and earnings growth

New minor risk - Profitability

SAB Biotherapeutics, Inc. to Report Q1, 2026 Results on May 12, 2026

Sab Biotherapeutics, Inc. Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes

Investor sentiment deteriorates as stock falls 19%

SAB Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999728 million.

SAB Biotherapeutics Inc Announces Additional Phase 1 Data for SAB 142 in Adult Patients with Established Autoimmune Type 1 Diabetes

SAB Biotherapeutics, Inc. Announces Board Changes ,Effective January 7, 2026

No longer forecast to breakeven

SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

First Patient Dosed in SAB Biotherapeutics, Inc.'S Safeguard Clinical Trial of Sab-142 for the Treatment of Stage 3 T1d

New minor risk - Profitability

SAB Biotherapeutics, Inc. Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

Sab Biotherapeutics, Inc. to Present Data Showcasing Progress in the Development of SAB-142 At the Asian Conference on Innovative Therapies for Diabetes Management

We Think SAB Biotherapeutics (NASDAQ:SABS) Can Afford To Drive Business Growth

Forecast to breakeven in 2025

New major risk - Shareholder dilution

SAB Biotherapeutics, Inc. Highlights Data in Multiple Presentations at EASD

Price target decreased by 16% to US$9.60

First half 2025 earnings released: US$1.65 loss per share (vs US$1.34 loss in 1H 2024)

SAB Biotherapeutics, Inc. announced that it has received $175 million in funding from a group of investors

SAB Biotherapeutics, Inc. announced that it expects to receive $175 million in funding from a group of investors

SAB Biotherapeutics, Inc., Annual General Meeting, Jul 17, 2025

First quarter 2025 earnings released: US$0.56 loss per share (vs US$0.54 loss in 1Q 2024)

Consensus revenue estimates decrease by 50%, EPS upgraded

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

Third quarter 2024 earnings released: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

Price target decreased by 35% to US$13.00

Consensus revenue estimates increase by 30%

Sab Bio Announces Founding of Clinical Advisory Board to Guide the Development of Sab-142 for Type 1 Diabetes

SAB Biotherapeutics, Inc. Appoints Lucy to as Chief Financial Officer, Effective August 12, 2024

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 27, 2024

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

SAB Biotherapeutics, Inc. announced delayed 10-Q filing

SAB Biotherapeutics, Inc. Appoints Jay Skyler, Md, to the Board of Directors

SAB Biotherapeutics, Inc. Provides SAB-142 Trial Update

Price target increased by 25% to US$25.00

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

SAB Biotherapeutics, Inc. Announces CEO Changes

SAB Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Shareholder dilution

SAB Biotherapeutics Announces Commencement of the Human Phase 1 Clinical Trial with Sab-142

SAB Biotherapeutics, Inc. Appoints Katie Ellias to the Board of Directors

Consensus revenue estimates increase by 61%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 22% to US$2.50

SAB Biotherapeutics, Inc. Appoints Michael G. King Jr. as Chief Financial Officer

SAB Biotherapeutics Appoints Andrew Moin to Board of Directors

Consensus revenue estimates decrease by 51%, EPS upgraded

Consensus revenue estimates decrease by 81%, EPS upgraded

SAB Biotherapeutics, Inc., Annual General Meeting, Jun 29, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

SAB Biotherapeutics, Inc. Announces First Publication of Promising Nonclinical Data for Sab-183 Against Pneumonic Plague in the Journal Antibodies

SAB Biotherapeutics Announces Progress on U.S. FDA's Phased Review of Company's DiversitAb Platform

SAB Biotherapeutics, Inc. Presents Positive Phase 1 and 2a Data for SAB-176 Influenza Immunotherapy at ISIRV-AVG Conference

Consensus revenue estimates decrease by 56%, EPS upgraded

Improved Revenues Required Before SAB Biotherapeutics, Inc. (NASDAQ:SABS) Stock's 42% Jump Looks Justified

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.63 loss in FY 2021)

Analysts Are Betting On SAB Biotherapeutics, Inc. (NASDAQ:SABS) With A Big Upgrade This Week

SAB Biotherapeutics, Inc. Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

SAB Biotherapeutics Novel Diversitab(Tm) Platform Proven to Develop Anti-Idiotype Antibodies to Help Treat Autoimmune Diseases

SAB Biotherapeutics, Inc. announced that it has received $7.884 million in funding

SAB Biotherapeutics Inc. Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes

Need To Know: Analysts Are Much More Bullish On SAB Biotherapeutics, Inc. (NASDAQ:SABS) Revenues